ArticleApplied microbiology and biotechnology2026
Activation of a gene cluster in Streptomyces lavendulae subsp. lavendulae CCM 3239 induced strevertene production.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genome of Streptomyces lavendulae subsp. lavendulae CCM 3239 contains 36 biosynthetic gene clusters (BGCs) that are cryptic or silent, except for the previously characterized aromatic polyketide auricin. In this work, we present a simple strategy to activate BGCs in this strain by replacing the native promoter with the strong kasOp* promoter via homologous recombination. This approach was validated by strong indigoidine production following insertion of kasOp* upstream of the silent bpsA gene. Using this strategy, we activated a silent BGC encoding a type I polyketide synthase (PKS). Interestingly, insertion of kasOp* at different positions within this BGC-upstream of the SLAV_02840 and SLAV_02776 genes-led to the production of distinct compounds, both exhibiting polyene spectral features and antifungal activity. Both compounds were isolated, and structural analysis revealed that they were similar to strevertenes; consequently, they were named strevertene A2 and X. A database search indicated that their structures corresponded to the known compounds RKGS-A2215A and AB023a. In silico analysis of the biosynthetic enzymes encoded by this strevertene (stv) BGC enabled us to propose a biosynthetic model consistent with the observed induction in the mutant strains S. lavendulae kasOp::2776 and S. lavendulae kasOp::2840. The analysis also suggested that strevertene X is an intermediate in the formation of the final polyene, strevertene A2. Notably, strevertene X exhibited approximately twofold higher antifungal activity than strevertene A2. KEY POINTS: • Strategy for activating BGCs by introducing a strong kasOp* promoter. • Efficient activation of the silent bpsA gene for indigoidine. • Activation of silent BGC for type I PKS for polyenes strevertene A2 and X.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.